Novo Nordisk stock slips premarket as China court backs key semaglutide patent
Novo Nordisk ADRs fell 0.7% premarket after China’s Supreme People’s Court upheld the company’s semaglutide compound patent. The patent covers the active ingredient in Wegovy, Ozempic, and Rybelsus. Investors are watching the early U.S. launch of the Wegovy pill and await the next results update in February.